Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer.
Elena IvanovaMari KuraguchiMan XuAndrew J PortellLuke J TausIrmina DialaAlshad S LalaniJihyun ChoiEmily S ChambersShuai LiShengwu LiuTing ChenThanh U BarbieGeoffrey R OxnardJacob J HaworthKwok-Kin WongSuzanne E DahlbergAmir A ArefDavid A BarbieMagda BahcallCloud P PaweletzPasi A JännePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The XDOTS platform can be used to evaluate therapies and therapeutic combinations ex vivo using PDX tumors. This approach may accelerate the identification and clinical development of therapies for targets with no or few existing models and/or therapies.